共 50 条
- [21] Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic ArthritisARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4229 - 4230FitzGerald, OliverGladman, DafnaMease, Philip J.Ritchlin, ChristopherSmolen, JosefGao, LuHu, SarahNowak, MiroslawaBanerjee, SubhashisCatlett, Ian M.
- [22] Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (Tyk2) Inhibitor, in Patients With Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 TrialJOURNAL OF RHEUMATOLOGY, 2024, 51 : 31 - 32Mosca, MartaArnaud, LaurentAskanase, AncaHobar, CoburnBecker, BrandonSinghal, ShalabhBanerjee, SubhashisPomponi, SamanthaChoi, JiyoonColes, AdrianTouma, ZahiKeeling, StephanieStrand, Vibeke
- [23] Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 TrialARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4611 - 4614Mosca, MartaArnaud, LaurentAskanase, AncaHobar, CoburnBecker, BrandonSinghal, ShalabhBanerjee, SubhashisPomponi, SamanthaChoi, JiyoonColes, AdrianStrand, Vibeke
- [24] Exposure-efficacy response modelling of bms-986165, a selective oral tyrosine kinase 2 (TYK2) inhibitor, in a phase 2 study in psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 36 - 36Girgis, I.Chimalakonda, A.Kundu, S.Throup, J.Banerjee, S.
- [25] Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 8953 - 8972Moslin, RyanZhang, YanleiWrobleski, Stephen T.Lin, ShuqunMertzman, MichaelSpergel, StevenTokarski, John S.Strnad, JoannGillooly, KathleenMcIntyre, Kim W.Zupa-Fernandez, AdrianaCheng, LihongSun, HuadongChaudhry, CharuHuang, ChristineD'Arienzo, CeliaHeimrich, ElizabethYang, XiaoxiaMuckelbauer, Jodi K.Chang, ChiehYingTredup, JeffreyMulligan, DawnXie, DianlinAranibar, NellyChiney, ManojBurke, James R.Lombardo, LouisCarter, Percy H.Weinstein, David S.
- [26] Selective inhibition of tyrosine kinase 2 (TYK2) improves molecular, cellular, and clinical biomarkers associated with efficacy in psoriasis without impacting Janus kinase (JAK) pathwaysJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 24 - 24Catlett, IanHu, SarahBanerjee, SubhashisGordon, KennethKruger, James
- [27] Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjectsJOURNAL OF CROHNS & COLITIS, 2019, 13 : S277 - S278Chimalakonda, A.Jones, J., IIIDockens, R.Throup, J.Banerjee, S.Girgis, I.
- [28] EFFICACY OF THE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR TAK-279 IN TWO PRECLINICAL MOUSE MODELS OF COLITISGASTROENTEROLOGY, 2024, 166 (05) : S1399 - S1399Kong, Kok-FaiKhan, Md A. WadudSingh, NamitaVan Anh NguyenWilson, ElizabethTang, JayMarusic, SuzanaXia, GuliangPetrakis, IoannisNguyen, Deborah G.
- [29] Potent and Selective Tyk2 Inhibitor Highly Efficacious in Rodent Models of Inflammatory Bowel Disease and PsoriasisARTHRITIS & RHEUMATOLOGY, 2016, 68Miao, WenyanMasse, CraigGreenwood, JeremyKapeller, RosanaWestlin, William
- [30] DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUSANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1463 - 1463Arriens, C.Askanase, A.Furie, R.Morand, E. F.Van Vollenhoven, R.Connors, K.Davey, M.Delev, N.Shah, V.Stevens, A.Wegman, T.Hobar, C.